OHARA Pharmaceutical Co.,Ltd. | 大原薬品工業株式会社

Entirely from the patients' perspective
Providing dependable pharmaceuticals
for the future of medicine

Ohara Pharmaceutical Co.,Ltd.

News Release

June 23, 2021
Recombinant Chimeric Monoclonal Antibody "Unituxin®" Marketing Authorization Approval
March 29, 2021
Glucarpidase (Genetical Recombination)"OP-07" Application Filed for Marketing Authorization for Methotrexate Intoxication
February 25, 2021
Ohara Pharmaceutical is introduced in Newsweek International Edition
September 24, 2020
Recombinant Chimeric Monoclonal Antibody "Dinutuximab (OP-08)":Application Filed for Marketing Authorization for Neuroblastoma
August 17, 2020
Recombinant Chimeric Monoclonal Antibody “Dinutuximab (OP-08)” Receives Orphan Drug Designation for Neuroblastoma from MHLW